Liquid Strategies Insights & Commentary

Why Novavax?

Author: Megan Delaney


In a previous blog post, we discussed how a potential coronavirus vaccine would affect the market. In July, both Pfizer and a lesser-known company, Novavax, were both awarded almost 2 billion dollars in funding from the government, with the the government placing orders for 100 million doses if the vaccine proves effective. The vaccine would be made available to Americans at no cost, but it’s unclear how they will determine who would receive the first doses of the vaccine and how the decision would be made.

Read More

Topics: COVID-19, coronavirus, vaccine

Liquid Strategies Blog

This is where our team takes the opportunity to discuss Market Observations, as well as Portfolio Manager Commentary.

To receive our insights in your inbox, please subscribe below.

Featured White Paper

New call-to-action

Recent Insights

Subscribe Form